Advertisement

Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype

Published:January 16, 2017DOI:https://doi.org/10.1016/j.ajog.2017.01.003

      Background

      Women with polycystic ovarian syndrome have a high prevalence of metabolic syndrome and type 2 diabetes mellitus. Blacks and Hispanics have a high morbidity and mortality due to cardiovascular disease and diabetes mellitus in the general population. Since metabolic syndrome is a risk factor for development of type 2 diabetes and cardiovascular disease, understanding any racial and ethnic differences in metabolic syndrome among women with polycystic ovarian syndrome is important for prevention strategies. However, data regarding racial/ethnic differences in metabolic phenotype among women with polycystic ovary syndrome are inconsistent.

      Objective

      We sought to determine if there are racial/ethnic differences in insulin resistance, metabolic syndrome, and hyperandrogenemia in women with polycystic ovarian syndrome.

      Study Design

      We conducted secondary data analysis of a prospective multicenter, double-blind controlled clinical trial, the Pregnancy in Polycystic Ovary Syndrome II study, conducted in 11 academic health centers. Data on 702 women with polycystic ovarian syndrome aged 18-40 years who met modified Rotterdam criteria for the syndrome and wished to conceive were included in the study. Women were grouped into racial/ethnic categories: non-Hispanic whites, non-Hispanic blacks, and Hispanic. The main outcomes were the prevalence of insulin resistance, metabolic syndrome, and hyperandrogenemia in the different racial/ethnic groups.

      Results

      Body mass index (35.1 ± 9.8 vs 35.7 ± 7.9 vs 36.4 ± 7.9 kg/m2) and waist circumference (106.5 ± 21.6 vs 104.9 ± 16.4 vs 108.7 ± 7.3 cm) did not differ significantly between non-Hispanic white, non-Hispanic black, and Hispanic women. Hispanic women with polycystic ovarian syndrome had a significantly higher prevalence of hirsutism (93.8% vs 86.8%), abnormal free androgen index (75.8% vs 56.5%), abnormal homeostasis model assessment (52.3% vs 38.4%), and hyperglycemia (14.8% vs 6.5%), as well as lower sex hormone binding globulin compared to non-Hispanic whites. Non-Hispanic black women had a significantly lower prevalence of metabolic syndrome (24.5% vs 42.2%) compared with Hispanic women, and lower serum triglyceride levels compared to both Hispanics and non-Hispanic whites (85.7 ± 37.3 vs 130.2 ± 57.0 vs 120.1 ± 60.5 mg/dL, P < .01), with a markedly lower prevalence of hypertriglyceridemia (5.1% vs 28.3% vs 30.5%, P < .01) compared to the other 2 groups.

      Conclusion

      Hispanic women with polycystic ovarian syndrome have the most severe phenotype, both in terms of hyperandrogenism and metabolic criteria. Non-Hispanic black women have an overall milder polycystic ovarian syndrome phenotype than Hispanics and in some respects, than non-Hispanic white women.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kurian A.K.
        • Cardarelli K.M.
        Racial and ethnic differences in cardiovascular disease risk factors: a systematic review.
        Ethn Dis. 2007; 17: 143-152
        • Mensah G.A.
        • Brown D.W.
        An overview of cardiovascular disease burden in the United States.
        Health Aff (Millwood). 2007; 26: 38-48
        • Dekker J.M.
        • Girman C.
        • Rhodes T.
        • et al.
        Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.
        Circulation. 2005; 112: 666-673
        • Hanley A.J.
        • Karter A.J.
        • Williams K.
        • et al.
        Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study.
        Circulation. 2005; 112: 3713-3721
        • Park Y.W.
        • Zhu S.
        • Palaniappan L.
        • Heshka S.
        • Carnethon M.R.
        • Heymsfield S.B.
        The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.
        Arch Intern Med. 2003; 163: 427-436
        • Sumner A.E.
        Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults.
        J Pediatr. 2009; 155 (S7.e-11)
        • Walker S.E.
        • Gurka M.J.
        • Oliver M.N.
        • Johns D.W.
        • DeBoer M.D.
        Racial/ethnic discrepancies in the metabolic syndrome begin in childhood and persist after adjustment for environmental factors.
        Nutr Metab Cardiovasc Dis. 2012; 22: 141-148
        • Hillman J.K.
        • Johnson L.N.
        • Limaye M.
        • Feldman R.A.
        • Sammel M.
        • Dokras A.
        Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS.
        Fertil Steril. 2014; 101 ([corrected]): 530-535
        • Ehrmann D.A.
        • Liljenquist D.R.
        • Kasza K.
        • Azziz R.
        • Legro R.S.
        • Ghazzi M.N.
        Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2006; 91: 48-53
        • Welt C.K.
        • Arason G.
        • Gudmundsson J.A.
        • et al.
        Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations.
        J Clin Endocrinol Metab. 2006; 91: 4361-4368
        • Ehrmann D.A.
        • Kasza K.
        • Azziz R.
        • Legro R.S.
        • Ghazzi M.N.
        Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2005; 90: 66-71
        • Ladson G.
        • Dodson W.C.
        • Sweet S.D.
        • et al.
        Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study.
        Fertil Steril. 2011; 96: 224-229.e2
        • Legro R.S.
        • Myers E.R.
        • Barnhart H.X.
        • et al.
        The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects.
        Fertil Steril. 2006; 86: 914-933
        • Legro R.S.
        • Brzyski R.G.
        • Diamond M.P.
        • et al.
        The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial.
        Fertil Steril. 2014; 101: 258-269.e8
        • Legro R.S.
        • Brzyski R.G.
        • Diamond M.P.
        • et al.
        Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.
        N Engl J Med. 2014; 371: 119-129
        • Legro R.S.
        • Kunselman A.R.
        • Brzyski R.G.
        • et al.
        The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.
        Contemp Clin Trials. 2012; 33: 470-481
        • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
        Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
        Fertil Steril. 2004; 81: 19-25
        • Golden S.H.
        • Brown A.
        • Cauley J.A.
        • et al.
        Health disparities in endocrine disorders: biological, clinical, and nonclinical factors–an Endocrine Society scientific statement.
        J Clin Endocrinol Metab. 2012; 97: E1579-E1639
        • Legro R.S.
        • Schlaff W.D.
        • Diamond M.P.
        • et al.
        Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism.
        J Clin Endocrinol Metab. 2010; 95: 5305-5313
        • Miller K.K.
        • Rosner W.
        • Lee H.
        • et al.
        Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods.
        J Clin Endocrinol Metab. 2004; 89: 525-533
        • Hatch R.
        • Rosenfield R.L.
        • Kim M.H.
        • Tredway D.
        Hirsutism: implications, etiology, and management.
        Am J Obstet Gynecol. 1981; 140: 815-830
        • Kauffman R.P.
        • Baker V.M.
        • Dimarino P.
        • Gimpel T.
        • Castracane V.D.
        Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations.
        Am J Obstet Gynecol. 2002; 187: 1362-1369
        • Alberti K.G.
        • Eckel R.H.
        • Grundy S.M.
        • et al.
        Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
        Circulation. 2009; 120: 1640-1645
      1. Framingham Heart Study. Available at: http://wwwframinghamheartstudyorg. Accessed June 9, 2015.

        • Haffner S.M.
        • D'Agostino R.
        • Saad M.F.
        • et al.
        Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study.
        Diabetes. 1996; 45: 742-748
        • Dunaif A.
        • Sorbara L.
        • Delson R.
        • Green G.
        Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women.
        Diabetes. 1993; 42: 1462-1468
        • Nestler J.E.
        • Powers L.P.
        • Matt D.W.
        • et al.
        A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
        J Clin Endocrinol Metab. 1991; 72: 83-89
        • DeUgarte C.M.
        • Woods K.S.
        • Bartolucci A.A.
        • Azziz R.
        Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism.
        J Clin Endocrinol Metab. 2006; 91: 1345-1350
        • Knochenhauer E.S.
        • Key T.J.
        • Kahsar-Miller M.
        • Waggoner W.
        • Boots L.R.
        • Azziz R.
        Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.
        J Clin Endocrinol Metab. 1998; 83: 3078-3082
        • Wang E.T.
        • Kao C.N.
        • Shinkai K.
        • Pasch L.
        • Cedars M.I.
        • Huddleston H.G.
        Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study.
        Fertil Steril. 2013; 100: 214-218
        • Glueck C.J.
        • Papanna R.
        • Wang P.
        • Goldenberg N.
        • Sieve-Smith L.
        Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
        Metabolism. 2003; 52: 908-915
        • Apridonidze T.
        • Essah P.A.
        • Iuorno M.J.
        • Nestler J.E.
        Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
        J Clin Endocrinol Metab. 2005; 90: 1929-1935
        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • et al.
        Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association.
        Circulation. 2012; 125: 188-197
        • Sumner A.E.
        • Zhou J.
        • Doumatey A.
        • et al.
        Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention.
        CVD Prev Control. 2010; 5: 75-80
        • McLaughlin T.
        • Abbasi F.
        • Cheal K.
        • Chu J.
        • Lamendola C.
        • Reaven G.
        Use of metabolic markers to identify overweight individuals who are insulin resistant.
        Ann Intern Med. 2003; 139: 802-809
        • Koval K.W.
        • Setji T.L.
        • Reyes E.
        • Brown A.J.
        Higher high-density lipoprotein cholesterol in African-American women with polycystic ovary syndrome compared with Caucasian counterparts.
        J Clin Endocrinol Metab. 2010; 95: E49-E53
        • Kauffman R.P.
        • Baker T.E.
        • Graves-Evenson K.
        • Baker V.M.
        • Castracane V.D.
        Lipoprotein profiles in Mexican American and non-Hispanic white women with polycystic ovary syndrome.
        Fertil Steril. 2011; 96: 1503-1507
        • Sumner A.E.
        “Half the dsylipidemia of insulin resistance” is the dyslipidemia [corrected] of insulin-resistant blacks.
        Ethn Dis. 2009; 19: 462-465
        • Lopes H.F.
        • Morrow J.D.
        • Stojiljkovic M.P.
        • Goodfriend T.L.
        • Egan B.M.
        Acute hyperlipidemia increases oxidative stress more in African Americans than in white Americans.
        Am J Hypertens. 2003; 16: 331-336